Results 171 to 180 of about 61,313 (265)

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor? [PDF]

Endocr Oncol
Wu X, Tian W, Wang Y.
europepmc   +1 more source

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background For patients with unfavorable intermediate or high risk localized prostate cancer receiving definitive radiotherapy, androgen deprivation therapy reduces recurrence and improves survival but is underutilized due to toxicity concerns. Patients who forgo initial ADT may later require salvage ADT.
Jiaye Shen, Aaron J. Katz, Yahui Xie, Ronald C. Chen, Mutlay Sayan   +4 more
wiley   +1 more source

Testosterone: Vital to female physiology. [PDF]

Womens Health (Lond)
Faucett K, Giles LA, Sing E.
europepmc   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Yuki Yoshikawa, Ryoichi Maenosono, Akihito Takeuchi, Kiyoshi Takahara, Seitetsu Sugiyama, Kazumasa Komura, Takafumi Yanagisawa, Wataru Fukuokaya, Takahiro Kimura, Kazutoshi Fujita   +14 more
wiley   +1 more source

Androgen loss accelerates brain tumour growth via HPA axis activation. [PDF]

Nature
Lee J, Chung YM, Silver DJ, Hao Y, Harwood DSL, Ealy A, Serapiglia AM, Curtin L, Benedetti JR, Ballard CAP, Lapsley K, Alvarez-Vazquez A, Goldberg J, Li C, Kaur S, Neal R, Wang SZ, Kay KE, Volovetz J, Hong ES, Fodor R, Jarmula J, Nicosia M, Rubin JB, Swanson KR, Ostrom QT, Panicker N, Kristensen BW, Berens M, Sharifi N, Lathia JD.   +30 more
europepmc   +1 more source

Management of De Novo miN1 Prostate Cancer in the PSMA‐PET Era

The Prostate, EarlyView.
ABSTRACT Background Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is reshaping nodal staging in prostate cancer by detecting regional lymph node metastases with greater accuracy than conventional imaging. This has created a new cohort of patients with N1M0 disease detectable only on advanced imaging, raising important ...
Thomas McMaster, Caitlin Ying Ming Louey, Jordan Santucci, Chloe Hobson, David D. Chen, Niranjan Sathianathen, Joseph Ischia, Damien M. Bolton, Nathan Lawrentschuck, Declan G. Murphy, Shankar Siva, Marlon Perera   +11 more
wiley   +1 more source

Immuno-inflammatory axis of menopausal dry eye: from hormonal fluctuations to ocular surface dysregulation. [PDF]

Front Immunol
Tian ZT, Jing CY, Liu HB, Jia XK, Xu HY, Pang YY.   +5 more
europepmc   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

The influence and mechanism of gut microbiota on spermatogenesis. [PDF]

Cell Biol Toxicol
Zhou X, Ge Z, Yang X, Liu Y, Li Y, Chen L, Lv L, Chen G.   +7 more
europepmc   +1 more source